4EGI-1 and other similar acting compounds, alone or in synergy with other kinase inhibitors, are being explored as cancer therapeutics and thus could be repurposed for neurodevelopmental disorders such as TSC (Mahalingam et al., 2014). This evidence concerns the gene TSC1 and neurodevelopmental disorder.